HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rao, A. V. Articles by Rizzieri, D. A. Search for Related Content PubMed PubMed Citation Articles by Rao, A. V. Articles by Rizzieri, D. A.

Radioimmunotherapy for Non-Hodgkin’s Lymphoma

Arati V. Rao, MD, Division of Medical Oncology and Division of Geriatrics, Duke University Medical Center and Durham Veterans Affairs Medical Center, 508 Fulton Street, Durham, NC 27710
Gamal Akabani, PhD, Department of Radiology, Duke University Medical Center, Durham, NC 27710
David A. Rizzieri, MD, Duke University Medical Center, 2400 Pratt Street, Suite 1100, Durham, NC 27710

Reprint Requests: Arati V. Rao, MD, Division of Medical Oncology and Division of Geriatrics, Duke University Medical Center and Durham Veterans Affairs Medical Center, 508 Fulton Street, Durham, NC 27710; Tel: 919-286-6944; Fax: 919-286-6896; Email: rao00012{at}mc.duke.edu.

Non-Hodgkin’s lymphoma (NHL) is the most common hematological malignancy in the United States with a rapidly increasing incidence. Most follicular NHL is indolent but incurable, whereas the more aggressive varieties do respond to therapy. Most patients with follicular NHL who transform to an aggressive NHL are very difficult to treat successfully. Treatment options have included chemotherapy, radiation, immunotherapy with monoclonal antibodies, alone or in combination, and hematopoietic stem cell transplantation. The efficacy of monoclonal antibodies is augmented when they are combined with a radioisotope like iodine-131 or yttrium-90. There have been a number of studies done in recent years studying the efficacy of this form of therapy, i.e., radioimmunotherapy (RIT) in patients with NHL. This review attempts to integrate the information from the various clinical trials done using RIT in patients with relapsed/refractory or newly diagnosed NHL and in hematopoietic stem cell transplantation. It also includes updates on the use of RIT in elderly patients and in patients with significant bone marrow involvement among other recent advances made in this field.

Key Words: Non-Hodgkin’s lymphoma • Radioimmunotherapy • Hematological malignancy • Monoclonal antibodies • Clinical trial

This article has been cited by other articles:

				A. A. McCormick, S. Reddy, S. J. Reinl, T. I. Cameron, D. K. Czerwinkski, F. Vojdani, K. M. Hanley, S. J. Garger, E. L. White, J. Novak, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study PNAS, July 22, 2008; 105(29): 10131 - 10136. [Abstract] [Full Text] [PDF]

				L. Leseux, S. M. Hamdi, T. al Saati, F. Capilla, C. Recher, G. Laurent, and C. Bezombes Syk-dependent mTOR activation in follicular lymphoma cells Blood, December 15, 2006; 108(13): 4156 - 4162. [Abstract] [Full Text] [PDF]